SCN patients are at risk of developing high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), with a reported median incidence of 21%, 15 years after initiation of CSF3 treatment.3 Here, CSF3 is linked to myelodysplastic syndrome.